Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Nebido in elderly men with symptomatic late-onset hypogonadism
2008-002053-20Phase 4Terminated
- Sponsor
- Bayer
- Start
- Aug 2008
- Countries
- 1
01
Overview
Phase 4, randomised, double-blind trial in Hypogonadism and Hypoandrogenism (TD) comparing Nebido 1000 mg with Placebo (2 arms). Primary endpoint: Change in lean body mass at 54 weeks. Started Aug 2008; status: terminated.
02
Drugs
testosterone undecanoate
03
Conditions
HypogonadismHypoandrogenism (TD)
Beyond the preview
Go deeper on 2008-002053-20.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2008-002053-20.